# PPLPHARMA (PPLPHARMA) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/pplpharma

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹207.64
- Change: +1.43%
- As of: 2026-09-18
- 1D return: +1.69%
- 5D return: -2.04%
- 1M return: -3.92%
- Latest complete quarter: fy27_q1

## Faxioms Analysis

_As of 2026-09-18_

### Technical Outlook

As of September 17, 2026, PPLPHARMA is trading at ₹204.71, with a daily technical stance indicating a potential shift from a bearish trend, as evidenced by the Supertrend indicator moving below the price. However, both weekly and monthly timeframes show a bullish trend, with prices above key moving averages and the Supertrend indicator.

The daily chart shows the price below the 20-day Exponential Moving Average (EMA) and Simple Moving Average (SMA), suggesting short-term weakness, while remaining above the 50-day EMA and SMA, and the 200-day SMA. This mixed picture on the daily timeframe, alongside an active 'Inside Bar' pattern formed on September 17, 2026, suggests a period of consolidation. The stock has experienced an extreme upward volume anomaly with price movement on September 8, 2026, with a volume ratio of 5.42.

Nearest support is observed around ₹203.06 (pivot), followed by ₹201.61. Resistance is noted at ₹207.27 and ₹207.34. The stock's current position is within its 252-day range, approximately 73% of the way up from the low. The annualized volatility stands at 37%, with a current drawdown of -21% and a maximum drawdown of -48%.

- Daily trend shows price below 20-day EMA and SMA, but above 50-day and 200-day SMAs.
- Weekly and monthly timeframes exhibit bullish trends with prices above key moving averages and Supertrend.
- Nearest support levels are ₹203.06 and ₹201.61.
- Nearest resistance levels are ₹207.27 and ₹207.34.
- Watch for a break above ₹207.27 for potential upward momentum, or a fall below ₹201.61 to indicate further weakness.

- Inside Bar
- Doji
- Shooting Star
- Outside Bar
- Bearish Engulfing Reversal
- Morning Star

### News Context

Piramal Pharma Solutions reported on September 16, 2026, that it has added a solar power plant at its Morpeth, UK facility, an initiative aimed at advancing its sustainability efforts. This development follows news from September 14 and 15, 2026, where it was disclosed that the same Morpeth facility received 7 observations from the US Food and Drug Administration (USFDA) following a Good Manufacturing Practices (GMP) inspection conducted between September 3-11, 2026. The company stated it would respond to these observations. In the market, Piramal Pharma Ltd. experienced a decline, quoting at ₹202.53, down 0.46% on September 16, 2026, marking its fifth consecutive session of losses. Over the past year, the stock has underperformed the NIFTY and the Nifty Pharma index.

- On September 16, 2026, Piramal Pharma Solutions announced the addition of a solar power plant at its Morpeth, UK site to enhance sustainability.
- The company's Morpeth facility received 7 observations from the USFDA after a GMP inspection from September 3-11, 2026, as reported on September 14 and 15, 2026.
- Piramal Pharma stated it will respond to the USFDA observations.
- Piramal Pharma Ltd. stock was trading at ₹202.53 on September 16, 2026, down 0.46% for the day and has fallen for five straight sessions.
- The stock has underperformed the NIFTY and Nifty Pharma index over the past year.

- Piramal Pharma Solutions Advances Sustainability Efforts with Solar Power Plant Addition at Morpeth, UK Site
- Piramal Pharma Ltd drops for fifth straight session
- Piramal Pharma shares fall 3% after USFDA issues 7 observations at UK facility
- Piramal Pharma Morpeth facility gets 7 US FDA observations
- Piramal Pharma gets 7 observations from US FDA at Morpeth UK facility

### What Changed

Piramal Pharma (PPLPHARMA) on the NSE experienced a slight price increase, closing at ₹204.71 on September 17, 2026, up from ₹202.37 the previous day. The provided evidence does not indicate any new filings or news developments that would explain this recent price movement. The company's common name remains Piramal Pharma, and its listing exchange is the NSE, consistent with prior context.

- On September 17, 2026, PPLPHARMA's closing price was ₹204.71, an increase from ₹202.37 on September 16, 2026.
- No new filings or news were reported for PPLPHARMA as of September 17, 2026.
- The company continues to be known as Piramal Pharma and is listed on the NSE.

### Official Filings

Piramal Pharma Limited has made two significant disclosures regarding its ownership structure and operational updates. On August 18, 2026, the company announced the completion of an acquisition of an additional 40.67% stake in Yapan Bio Private Limited for approximately ₹76 crores. This transaction increased Piramal Pharma's shareholding in Yapan Bio from 33.33% to 74.00%, converting Yapan Bio from an associate company into a subsidiary. The acquisition aims to integrate Yapan's large molecule capabilities into Piramal Pharma's service offerings. Separately, on August 24, 2026, Piramal Pharma released its Sustainability Report for the financial year 2025-26. The report highlighted a 22.6% reduction in Scope 1 and 2 Greenhouse Gas (GHG) emissions compared to the FY2022 baseline and ₹8.98 Crore spent on Corporate Social Responsibility (CSR) projects impacting approximately 1.8 million people. The company also disclosed upcoming investor meetings in September 2026, including engagements in the United Kingdom, India, and Singapore.

- On August 18, 2026, Piramal Pharma Limited acquired an additional 40.67% stake in Yapan Bio Private Limited for approximately ₹76 crores, making Yapan Bio a subsidiary.
- The acquisition increased Piramal Pharma's total shareholding in Yapan Bio to 74.00%.
- Piramal Pharma's Sustainability Report for FY2025-26, filed on August 24, 2026, reported a 22.6% reduction in Scope 1 and 2 GHG emissions against the FY2022 baseline.
- The company reported spending ₹8.98 Crore on CSR projects in FY2025-26.
- Piramal Pharma scheduled multiple analyst and institutional investor meetings for September 2026.

- Disclosure under Regulation 30 of Securities and Exchange Board of India(Listing Obligations and Disclosure Requirements) Regulations, 2015 FDA Inspection |SUBJECT: General Updates
- PIRAMAL PHARMA LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL
- Intimation of Schedule of Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- NAME(S)OF THE ACQUIRER AND ITS(PAC) : Deutsche Bank AG, Mumbai Branch
- Sustainability Report of Piramal Pharma Limited ( the Company ) for thefinancial year 2025-26-26 |SUBJECT: Updates
- NAME(S)OF THE ACQUIRER AND ITS(PAC) : Deutsche Bank AG, Mumbai Branch acting in its capacity as the onshore security agent for Lenders
- Piramal Pharma Limited has informed the Exchange about Acquisition |SUBJECT: Acquisition
- Piramal Pharma Limited has informed the Exchange regarding Acquisition (including agreement to acquire) |SUBJECT: Acquisition (including agreement to acquire)-XBRL
- PIRAMAL PHARMA LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL
- Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates

### Fundamentals

Piramal Pharma's reported results show fluctuations in its operating performance. Revenue from operations stood at ₹2,269.92 crore in Q1 FY2026-27, a decrease from ₹2,751.77 crore in Q4 FY2025-26 but an increase from ₹2,139.87 crore in Q3 FY2025-26. The company reported a Profit Before Exceptional Items and Tax of -₹27.02 crore in Q1 FY2026-27, a decline from ₹205.20 crore in Q4 FY2025-26, and a loss compared to the -₹63.01 crore in Q3 FY2025-26. Expenses have also varied, with total expenses at ₹2,386.35 crore in Q1 FY2026-27, compared to ₹2,592.63 crore in Q4 FY2025-26 and ₹2,246.12 crore in Q3 FY2025-26. Finance costs remained relatively stable, reported at ₹88.08 crore in Q1 FY2026-27, ₹82.99 crore in Q4 FY2025-26, and ₹89.24 crore in Q3 FY2025-26. The company's ability to translate revenue into profitability and manage its expense base will be key monitoring areas.

- Revenue from operations for Q1 FY2026-27 was ₹2,269.92 crore.
- Profit Before Exceptional Items and Tax in Q1 FY2026-27 was -₹27.02 crore.
- Total expenses in Q1 FY2026-27 were ₹2,386.35 crore.
- Finance costs in Q1 FY2026-27 were ₹88.08 crore.

### Bull Case

Piramal Pharma's monthly and weekly technical trends show constructive signals, with the monthly trend indicating a bullish Supertrend and the weekly trend also showing a bullish Supertrend. The company's year-to-date return was 0.21 and its 6-month return was 0.47, indicating positive performance over these periods. Additionally, the company has made efforts to advance its sustainability initiatives, such as adding a solar power plant at its Morpeth, UK site.

- The monthly trend shows a bullish Supertrend indicator as of 2026-09-17.
- The weekly trend also indicates a bullish Supertrend as of 2026-09-17.
- The company's year-to-date return was 0.21.
- The company's 6-month return was 0.47.

- Piramal Pharma Solutions Advances Sustainability Efforts with Solar Power Plant Addition at Morpeth, UK Site
- Piramal Pharma Ltd drops for fifth straight session
- Piramal Pharma shares fall 3% after USFDA issues 7 observations at UK facility
- Piramal Pharma Morpeth facility gets 7 US FDA observations
- Piramal Pharma gets 7 observations from US FDA at Morpeth UK facility

### Bear Case

Piramal Pharma's stock has experienced a decline, falling for five consecutive sessions as of September 13, 2026, and underperforming the Nifty Pharma index over the past year. This trend coincides with regulatory scrutiny, as the US Food and Drug Administration (USFDA) issued 7 observations following an inspection of the company's Morpeth facility in the UK between September 3-11, 2026. While the company stated it would respond to these observations, the event has cast a shadow on operational compliance. Technically, the daily trend shows the closing price below the 20-day exponential moving average, and the supertrend indicator is in a bearish direction, suggesting short-term weakness.

- The stock has declined for five consecutive sessions ending September 13, 2026.
- Piramal Pharma's stock has lost 17.48% in the last year, compared to a 8.14% loss in the Nifty.
- The USFDA issued 7 observations after inspecting the Morpeth, UK facility from September 3-11, 2026.
- The daily technical trend indicates a bearish supertrend direction as of September 17, 2026.

- Piramal Pharma Solutions Advances Sustainability Efforts with Solar Power Plant Addition at Morpeth, UK Site
- Piramal Pharma Ltd drops for fifth straight session
- Piramal Pharma shares fall 3% after USFDA issues 7 observations at UK facility
- Piramal Pharma Morpeth facility gets 7 US FDA observations
- Piramal Pharma gets 7 observations from US FDA at Morpeth UK facility

### FAQs

**What is the recent regulatory development concerning Piramal Pharma's UK facility?**

On September 14, 2026, Piramal Pharma disclosed that its Morpeth facility in the UK received 7 observations from the US FDA following an inspection conducted between September 3-11, 2026. The company stated it would respond to these observations.

**How has Piramal Pharma's stock performed recently compared to market indices?**

As of 13:19 IST on September 17, 2026, Piramal Pharma was trading at ₹202.53, down 0.46% for the day. In the past year, the stock has lost value compared to a 8.14% gain in the NIFTY and a 17.48% loss in the Nifty Pharma index.

**What are the key sustainability achievements reported by Piramal Pharma for FY2025-26?**

Piramal Pharma's Sustainability Report for the financial year 2025-26, released on August 24, 2026, highlighted a 22.6% reduction in Scope 1 and 2 GHG emissions against the FY2022 baseline. The company also reported spending ₹8.98 Crore on CSR projects that impacted approximately 1.8 million people.

**What is the current technical trend for Piramal Pharma based on daily and weekly indicators?**

As of the trading day ending September 17, 2026, the daily trend for Piramal Pharma shows a 'bearish' Supertrend direction with the closing price at ₹204.71, below the 20-day Exponential Moving Average (EMA) of ₹210.48. However, the weekly trend indicates a 'bullish' Supertrend direction, with the closing price above the 20-day EMA of ₹191.60.

- Piramal Pharma Solutions Advances Sustainability Efforts with Solar Power Plant Addition at Morpeth, UK Site
- Piramal Pharma Ltd drops for fifth straight session
- Piramal Pharma shares fall 3% after USFDA issues 7 observations at UK facility
- Piramal Pharma Morpeth facility gets 7 US FDA observations
- Piramal Pharma gets 7 observations from US FDA at Morpeth UK facility
- Disclosure under Regulation 30 of Securities and Exchange Board of India(Listing Obligations and Disclosure Requirements) Regulations, 2015 FDA Inspection |SUBJECT: General Updates
- PIRAMAL PHARMA LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL
- Intimation of Schedule of Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- NAME(S)OF THE ACQUIRER AND ITS(PAC) : Deutsche Bank AG, Mumbai Branch
- Sustainability Report of Piramal Pharma Limited ( the Company ) for thefinancial year 2025-26-26 |SUBJECT: Updates
## Technical analytics

- As of: 2026-09-18
- Daily trend: Weak Downtrend
- Weekly trend: Moderate Uptrend
- Pivot point: ₹204.47
- Risk regime: Price Risk Requires Attention

### Support levels
- 201.60562499999997
- 197.31375
- 196.885

### Resistance levels
- 220.00875000000002
- 226.81125
- 231.93

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +1.69% |
| return_10 | -2.95% |
| return_1m | -1.13% |
| return_1y | +2.38% |
| return_20 | -3.92% |
| return_3m | +29.94% |
| return_5 | -2.04% |
| return_6m | +45.44% |
| return_since_start | -19.40% |
| return_ytd | +22.53% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | elevated_risk |
| label | Price risk requires attention |
| summary | Recent drawdown or price variability is high enough to warrant closer monitoring. |
| maximum_drawdown | -48.39% |
| annualized_volatility | +36.57% |

## Quarterly financials

- Latest complete quarter: fy27_q1

# Revenue Grows 17% YoY, Operating Loss Narrows as Expenses Rise Slower

Piramal Pharma Limited reported a 17.4% increase in revenue from operations to ₹2,269.9 crore for the quarter ended 30 June 2026. The company’s net loss narrowed compared with the same quarter a year ago, as expenses grew at a slower pace than revenue. The quarter recorded no exceptional items, following a gain in the prior-year quarter and a significant charge in the preceding March quarter.

## Revenue and Expense Trends

Revenue from operations was ₹2,269.92 crore, up 17.4% from ₹1,933.71 crore in the first quarter of the previous year. Sequentially, revenue declined 17.5% from ₹2,751.77 crore in the March 2026 quarter. Including other income of ₹89.41 crore, total income reached ₹2,359.33 crore, an 18.4% increase year-on-year.

Total expenses rose 13.1% to ₹2,386.35 crore, a slower rate than revenue growth. Key expense components for the quarter were:

- Cost of materials consumed: ₹724.77 crore
- Purchases of stock-in-trade: ₹420.24 crore
- Changes in inventories of finished goods, work in progress and stock-in-trade: -₹292.74 crore (indicating an inventory build)
- Employee benefit expense: ₹675.63 crore
- Finance costs: ₹88.08 crore
- Depreciation: ₹223.55 crore
- Other expenses: ₹546.82 crore

The slower expense growth relative to revenue indicates operating leverage.

## Profitability and Margins

Profit before exceptional items and tax improved to a loss of ₹27.02 crore, compared with a loss of ₹118.33 crore a year ago. After accounting for exceptional items (nil this quarter versus a gain of ₹20.74 crore in the prior-year quarter), profit before tax narrowed to a loss of ₹27.02 crore (last year: loss of ₹97.59 crore).

Operating profit before interest, tax, depreciation and amortisation (EBITDA) was approximately ₹284.6 crore, yielding an EBITDA margin of 12.5% on revenue from operations.

## Exceptional Items and Tax

Exceptional items before tax were absent this quarter, contrasting with a gain of ₹20.74 crore in the same quarter last year and a substantial charge of ₹175.77 crore in the immediately preceding quarter (Q4 FY2025-26).

Tax expense rose sharply to ₹61.93 crore from ₹2.68 crore a year earlier. This increase widened the net loss from continuing operations to ₹88.95 crore, compared with ₹100.27 crore in the prior-year quarter. After including a share of profit from associates of ₹19.56 crore, the overall net loss for the period was ₹69.39 crore, compared with ₹81.70 crore last year.

## Comprehensive Income and EPS

Comprehensive income for the period was a loss of ₹99.94 crore, compared with a loss of ₹37.56 crore last year. The widening comprehensive loss was driven by other comprehensive income swinging from a gain of ₹44.14 crore a year ago to a loss of ₹30.55 crore in the current quarter.

Basic and diluted earnings per share from continuing operations was -₹0.52 per share, compared with -₹0.62 per share last year. There were no discontinued operations.

## Management Commentary

Piramal Pharma reported a strong Q1FY27 with consolidated revenue from operations rising 17% YoY to ₹2,270 crore, driven by healthy performance across all three businesses. EBITDA surged 72% to ₹285 crore, with margin expanding approximately 400 basis points to 12.5%, reflecting improved capacity utilization, pricing discipline, and operational excellence. Management, led by Chairperson Nandini Piramal, expressed confidence in sustaining revenue growth and significant profitability expansion through FY27, while remaining agile amid dynamic external conditions.

The CDMO segment delivered 19% YoY revenue growth, supported by broad-based performance across sites, an enhanced commercial team, and favorable tailwinds from increased biopharma funding and supply-chain diversification. However, management cautioned that customer decision-making timelines remain prolonged and emphasized that converting the strong RFP pipeline into orders is a key growth driver. The Complex Hospital Generics (CHG) business grew 17%, maintaining leadership in core therapies like US Sevoflurane and intrathecal Baclofen, with Kenalog® integration on track for supplies from Q2FY27. The Consumer Healthcare (PCH) business posted 15% growth, powered by Power Brands (+23%) and e-commerce (+40%), while premiumization and cost initiatives helped offset raw material inflation.

## Key Takeaway

Piramal Pharma’s first quarter of FY2026-27 showed a clear improvement in underlying operating results. Revenue grew 17.4% while expenses rose at a slower 13.1% rate, narrowing the pre-tax loss. EBITDA turned positive at ₹284.6 crore, reflecting a 12.5% margin on revenue. The net loss of ₹69.4 crore was smaller than last year’s ₹81.7 crore, though a sharp increase in tax expense to ₹61.9 crore limited the bottom-line improvement. The absence of exceptional items also simplified the profit comparison.

### Ratios

## Official filings

- 2026-09-18 — Generic Announcement: Piramal Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/PIRAMALPHARMA_18092026194214_SEIntimation.pdf)
- 2026-09-14 — Generic Announcement: Piramal Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/PIRAMALPHARMA_14092026195645_SE_Intimation-FDA_Inspection_Morpeth_.pdf)
- 2026-09-08 — Generic Announcement: Piramal Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_20978_WebXMLFile_20260908_153805020.xml)
- 2026-09-08 — Generic Announcement: Piramal Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/PIRAMALPHARMA_08092026153646_SEIntimation_Analyst_call.pdf)
- 2026-08-27 — Regulatory Filing: Piramal Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/PPLPHARMA_08272026184825_52968.zip)
- 2026-08-24 — Generic Announcement: Piramal Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/PIRAMALPHARMA_24082026170728_SE_Intimation-_Sustainability_report.pdf)
- 2026-08-21 — Regulatory Filing: Piramal Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/PIRAMAL_08212026124453_52764.zip)
- 2026-08-18 — Generic Announcement: Piramal Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Priyankamehta_18082026113757_SEDisclosure_CompletionofacquistioninYapan.pdf)
- 2026-08-18 — Generic Announcement: Piramal Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/REG30_Restructuring_20978_WebXMLFile_20260818_141237040.xml)
- 2026-08-10 — Generic Announcement: Piramal Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_20978_WebXMLFile_20260810_142226086.xml)
- 2026-08-10 — Generic Announcement: Piramal Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Priyankamehta_10082026142602_SEIntimation_Analyst_call.pdf)
- 2026-08-03 — Generic Announcement: Piramal Pharma Limited announced the resumption of operations at its manufacturing facilities in Ahmedabad, Gujarat, effective August 3rd, 2026, following a temporary suspension due to heavy rainfall and flooding. While limited restoration activities are ongoing, the company anticipates no material impact on its operations or financial performance and has initiated an insurance claim process. — [Official attachment](https://nsearchives.nseindia.com/corporate/PIRAMALPHARMA_03082026173517_Reg_30_Intimation_-_Resumption_of_operation.pdf)
- 2026-07-31 — Official Filing: Piramal Pharma Limited has disclosed the transcripts of its earnings call held on July 30, 2026. The transcripts were uploaded to the company's website on July 31, 2026, at 13:20:00, following prior intimation to the exchange on July 20, 2026. The call concluded at 10:30:00 on July 30, 2026.
- 2026-07-31 — Generic Announcement: Piramal Pharma Limited has made available the transcript of a conference call held on July 30, 2026, discussing its unaudited financial results for the quarter ended June 30, 2026. This transcript is accessible on the company's website. — [Official attachment](https://nsearchives.nseindia.com/corporate/Priyankamehta_31072026151132_PPL_TranscriptofAnalystMeet.pdf)
- 2026-07-30 — Generic Announcement: Piramal Pharma Limited has made the audio recording of its conference call on the unaudited financial results for the quarter ended June 30, 2026, available on its website. The conference call took place on July 30, 2026. This disclosure is in compliance with SEBI regulations. — [Official attachment](https://nsearchives.nseindia.com/corporate/Priyankamehta_30072026122530_SEIntimationAnalystcallAudio__002_.pdf)
- 2026-07-30 — Generic Announcement: Piramal Pharma Limited held its 6th Annual General Meeting on July 30, 2026, where all ten proposed resolutions were passed with the requisite majority. These resolutions included the adoption of the financial statements for the fiscal year ending March 31, 2026, the re-appointment of several directors including Peter DeYoung, Nathalie Leitch, Nandini Piramal, Sridhar Gorthi, and Peter Stevenson, ratification of cost auditor remuneration, and approval for the issuance of non-convertible debentures and the creation of security over subsidiary assets. — [Official attachment](https://nsearchives.nseindia.com/corporate/PIRAMALPHARMA_30072026201828_AGMOutcome.pdf)
- 2026-07-30 — Generic Announcement: Piramal Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_543635_307202612212_SAIIM_WebXMLFile_20260730_122104563.xml)
- 2026-07-29 — Generic Announcement: Piramal Pharma Limited announced its unaudited financial results for the first quarter ended June 30, 2026, reporting a 19% year-on-year revenue growth and a 72% increase in EBITDA. The company highlighted strong performance across its Contract Development and Manufacturing Organization (CDMO), Complex Hospital Generics, and Consumer Healthcare businesses. An investor conference call is scheduled for July 30, 2026, to discuss these results. — [Official attachment](https://nsearchives.nseindia.com/corporate/Priyankamehta_29072026205353_PressReleaseandInvestorPresentationQ127_sd.pdf)
- 2026-07-29 — Press Release: Piramal Pharma Limited announced its unaudited financial results for the first quarter ended June 30, 2026, reporting a 19% year-on-year revenue growth and a 72% increase in EBITDA. The company highlighted strong performance across its Contract Development and Manufacturing Organization (CDMO), Complex Hospital Generics, and Consumer Healthcare businesses. An investor conference call is scheduled for July 30, 2026, to discuss these results. — [Official attachment](https://nsearchives.nseindia.com/corporate/Priyankamehta_29072026204914_PressReleaseandInvestorPresentationQ127_sd.pdf)
- 2026-07-29 — Generic Announcement: On July 29, 2026, Piramal Pharma Limited's Nomination and Remuneration Committee approved the grant of up to 5,636,436 stock options under its Employee Stock Option and Incentive Plan 2022. These options, covering 5,636,436 equity shares, were granted at an exercise price of Rs. 10 per option. Vesting schedules vary by location, with options generally vesting in tranches starting July 29, 2027, and exercisable within five years of vesting, with specific timelines for US-based employees. — [Official attachment](https://nsearchives.nseindia.com/corporate/PIRAMALPHARMA_29072026171838_SE_Intimation_-_ESOP_Grant_2026-27.pdf)
- 2026-07-29 — Generic Announcement: Piramal Pharma Limited's Board of Directors approved the unaudited financial results for the quarter ended June 30, 2026, on July 29, 2026. Standalone results show revenue from operations of Rs. 1,124.95 crore and a net profit after tax of Rs. 113.48 crore. Consolidated results for the same period indicate revenue from operations of Rs. 2,269.92 crore and a net loss after tax of Rs. 69.39 crore. — [Official attachment](https://nsearchives.nseindia.com/corporate/Priyankamehta_29072026204343_PPL_OutcomeofBM_29072026_sd.pdf)
- 2026-07-29 — Earnings Presentation: Piramal Pharma Limited announced its unaudited financial results for the first quarter ended June 30, 2026, reporting a 19% year-on-year revenue growth and a 72% increase in EBITDA. The company highlighted strong performance across its Contract Development and Manufacturing Organization (CDMO), Complex Hospital Generics, and Consumer Healthcare businesses. An investor conference call is scheduled for July 30, 2026, to discuss these results. — [Official attachment](https://nsearchives.nseindia.com/corporate/Priyankamehta_29072026205131_PressReleaseandInvestorPresentationQ127_sd.pdf)
- 2026-07-24 — Generic Announcement: Piramal Pharma Limited temporarily suspended operations at its Ahmedabad, Gujarat facilities on July 24, 2026, due to heavy rainfall and flooding. The company is assessing the impact on assets and operations, with a gradual normalization expected in the coming days, subject to weather improvement. These facilities contribute less than 3% of the company's consolidated revenues, and assets are adequately insured. — [Official attachment](https://nsearchives.nseindia.com/corporate/PIRAMALPHARMA_24072026205512_Reg30IntimationAhmedabadoperationalimpact.pdf)
- 2026-07-20 — Official Filing: Piramal Pharma Limited will hold its Q1 FY2027 Earnings Conference Call on July 30, 2026, at 09:30:00 IST virtually. The call will discuss the company's Q1 FY2027 results. Contact person for this intimation is Gagan Borana.
- 2026-07-20 — Generic Announcement: Piramal Pharma Limited will host a conference call on July 30, 2026, from 9:30 AM to 10:15 AM IST to discuss its Q1 FY2027 results. The call is intended for investors and analysts. — [Official attachment](https://nsearchives.nseindia.com/corporate/Priyankamehta_20072026125849_Q1FY27_Analyst_Call_Intimation.pdf)

## News and market events

- 2026-09-16 — The Hindu: **Piramal Pharma Solutions Advances Sustainability Efforts with Solar Power Plant Addition at Morpeth, UK Site** — Piramal Pharma Solutions Advances Sustainability Efforts with Solar Power Plant Addition at Morpeth, UK Site — [Source](https://www.thehindu.com/brandhub/pr-release/piramal-pharma-solutions-advances-sustainability-efforts-with-solar-power-plant-addition-at-morpeth-uk-site/article71473374.ece)
- 2026-09-16 — BUSINESS: **Piramal Pharma Ltd drops for fifth straight session** — Piramal Pharma Ltd is quoting at Rs 202.53, down 0.46% on the day as on 13:19 IST on the NSE. The stock  in last one year as compared to a 8.14%  in NIFTY and a 17.48%  lost  in the Nifty Pharma index. — [Source](https://www.business-standard.com/markets/capital-market-news/piramal-pharma-ltd-drops-for-fifth-straight-session-126091600629_1.html)
- 2026-09-15 — CNBC-TV18: **Piramal Pharma shares fall 3% after USFDA issues 7 observations at UK facility** — The USFDA issued a Form 483 following a Good Manufacturing Practices (GMP) inspection of the facility, Piramal Pharma said in a stock exchange filing on Monday. — [Source](https://www.cnbctv18.com/market/piramal-pharma-share-price-fall-usfda-form-483-morpeth-uk-facility-gmp-inspection-7-observations-19990884.htm)
- 2026-09-14 — The Hindu: **Piramal Pharma Morpeth facility gets 7 US FDA observations** — Piramal Pharma’s Morpeth facility in the UK received 7 US FDA observations after an inspection from September 3-11, 2026. The company will respond. — [Source](https://www.thehindubusinessline.com/companies/piramal-pharmas-uk-facility-receives-7-observations-from-us-fda-inspection/article71466358.ece)
- 2026-09-14 — CNBC-TV18: **Piramal Pharma gets 7 observations from US FDA at Morpeth UK facility** — Shares of Piramal Pharma Ltd ended at ₹211.90, down by ₹0.60, or 0.28%, on the BSE. — [Source](https://www.cnbctv18.com/market/stocks/piramal-pharma-share-price-gets-7-observations-from-us-fda-at-morpeth-uk-facility-19990378.htm)
- 2026-09-09 — BUSINESSTODAY: **Piramal Pharma likely to hit fresh highs as CDMO recovery lifts EBITDA, says Quest CIO** — Piramal Pharma, Piramal Pharma stock outlook, Piramal Pharma share price, Rakesh Vyas, Quest Investment Managers, CDMO stocks India, pharma stocks India, Piramal Pharma EBITDA growth, Piramal Pharma earnings recovery, destocking impact pharma, contract development and manufacturing, Indian pharma sector outlook, CDMO business growth, Piramal Pharma all-time high, healthcare stocks India, pharma market analysis, operating leverage in pharma, midcap pharma stocks, Indian stock market pharma picks, Business Today pharma news — [Source](https://www.businesstoday.in/markets/stocks/story/piramal-pharma-likely-to-hit-fresh-highs-as-cdmo-recovery-lifts-ebitda-says-quest-cio-554301-2026-09-09)
- 2026-09-08 — Mint: **Stock market today: Trade guide for Sensex, Nifty 50, crude oil to gold | eight stocks to buy** — Stock market today: Indian stock market indices Sensex and Nifty 50 are set for a lower open on 8 September amid mixed global cues. Nifty 50 closed below 23,800, signaling bearish momentum, while elevated crude oil prices and geopolitical tensions raise concerns over inflation and market sentiment. — [Source](https://www.livemint.com/market/stock-market-news/stock-market-today-trade-guide-for-sensex-nifty-50-crude-oil-to-gold-eight-stocks-to-buy-11788828251128.html)
- 2026-09-02 — BUSINESS: **Sai Life Science surges 8% in two days; stock hits new high in weak market** — In the past month, Sai Life Science stock surged 19 per cent, against a 2.8 per cent decline in the BSE Sensex. — [Source](https://www.business-standard.com/markets/news/sai-life-science-surges-8-in-two-days-stock-hits-new-high-in-weak-market-126090200295_1.html)
- 2026-08-27 — Economic Times: **US envoy Sergio Gor meets Piramal Group Chairman Ajay Piramal, discusses expansion plans in US** — US Ambassador Sergio Gor met Piramal Group Chairman Ajay Piramal discussing economic ties. Gor lauded Piramal's growing United States footprint as a strong investment example. The Ambassador also met Cummins CEO Jennifer Rumsey regarding company operations. India's trade surplus with the United States narrowed in the recent fiscal year. These meetings highlight strengthening bilateral cooperation and business expansion opportunities. — [Source](https://economictimes.indiatimes.com/news/company/corporate-trends/us-envoy-sergio-gor-meets-piramal-group-chairman-ajay-piramal-discusses-expansion-plans-in-us/articleshow/133562094.cms)
- 2026-08-26 — The Hindu: **Piramal Pharma Strengthens Future Ready Operations with 22.6% Emissions Reduction, 41% Renewable Energy and Zero USFDA OAI Observations** — Piramal Pharma Strengthens Future Ready Operations with 22.6% Emissions Reduction, 41% Renewable Energy and Zero USFDA OAI Observations — [Source](https://www.thehindubusinessline.com/brandhub/pr-release/piramal-pharma-strengthens-future-ready-operations-with-226-emissions-reduction-41-renewable-energy-and-zero-usfda-oai-observations/article71393459.ece)
- 2026-08-26 — The Hindu: **Piramal Pharma Strengthens Future Ready Operations with 22.6% Emissions Reduction, 41% Renewable Energy and Zero USFDA OAI Observations** — Piramal Pharma Strengthens Future Ready Operations with 22.6% Emissions Reduction, 41% Renewable Energy and Zero USFDA OAI Observations — [Source](https://www.thehindu.com/brandhub/pr-release/piramal-pharma-strengthens-future-ready-operations-with-226-emissions-reduction-41-renewable-energy-and-zero-usfda-oai-observations/article71393455.ece)
- 2026-08-19 — Mint: **Buy or sell: Gift Nifty hints at a volatile session, Vaishali Parekh recommends three stocks to buy today — 19 August** — Buy or sell: Vaishali Parekh recommends three stocks to buy today — Data Patterns, L&T Finance, and Piramal Pharma — [Source](https://www.livemint.com/market/stock-market-news/buy-or-sell-gift-nifty-hints-at-a-volatile-session-vaishali-parekh-recommends-three-stocks-to-buy-today-19-august-11787103794295.html)
- 2026-08-19 — The Hindu: **Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited** — Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited — [Source](https://www.thehindu.com/brandhub/pr-release/piramal-pharma-limited-completes-acquisition-of-controlling-stake-in-yapan-bio-private-limited/article71363142.ece)
- 2026-08-14 — CNBC-TV18: **Sensex Today | Stock Market LIVE Updates: Zee Ent shares soar 7%; Nifty down over 80 pts** — Sensex Today | Stock Market LIVE Updates: The markets are under pressure, with the Nifty index falling towards the 24,300 mark. The Nifty Bank is also trading on similar ground, falling below the 57,500 mark. Tata Motors PV, Hindalco, Max Health are the top losers. — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-nifty-50-today-sensex-hdfc-bank-nifty-bank-q1-earnings-tata-motors-max-fin-defence-bdl-share-price-liveblog-19969121.htm)
- 2026-08-13 — CNBC-TV18: **Stocks to Watch for August 14: Tata Motors PV, LG Electronics, Honasa Consumer, Max Fin Services and more** — From Honasa Consumer reporting a 118.4% year-on-year rise in net profit to Birla Estates entering Navi Mumbai’s redevelopment market with a Vashi housing project, these are the stocks to track ahead of Friday’s trading session. Investors will also watch Borosil, Cochin Shipyard and CSM Technologies, which are scheduled to announce their June-quarter results tomorrow. — [Source](https://www.cnbctv18.com/photos/market/stocks-to-watch-for-august-14-tata-motors-pv-lg-electronics-honasa-consumer-max-fin-services-and-more-19968900.htm)
- 2026-08-13 — CNBC-TV18: **Piramal Pharma Block Deal: Seller likely to offload 6% stake for around ₹1,750 crore** — Shares of Piramal Pharma Ltd ended at ₹212.95, up by ₹2.60, or 1.24%, on the BSE. — [Source](https://www.cnbctv18.com/market/stocks/piramal-pharma-share-price-block-deal-seller-likely-to-offload-6-stake-for-around-rs-1750-crore-19968808.htm)
- 2026-08-04 — NEWS.WEBINDIA123.COM: **Piramal Pharma Solutions Expands Peptide API Facility with Advanced Spray Drying Suite** — PRNewswire — [Source](https://news.webindia123.com/news/articles/business/20260804/4483113.html)
- 2026-07-31 — BUSINESSTODAY: **Piramal Pharma shares: Expert sees Rs 238 target after breakout; should you sell on rally?** — Piramal Pharma stock, Piramal Pharma target price, Piramal Pharma technical analysis, Piramal Pharma resistance levels, Piramal Pharma breakout, Pharma stocks to buy, Pradeep Halder stock recommendation, Indian pharma stocks, Stock market today, Piramal Pharma news — [Source](https://www.businesstoday.in/markets/story/piramal-pharma-share-price-expert-sees-rs-238-target-after-breakout-should-you-sell-on-rally-546484-2026-07-31)
- 2026-07-31 — MONEYCONTROL: **Q1 growth has been broad-based across businesses, says Piramal Pharma chairperson Nandini Piramal** — Nandini Piramal, Piramal Pharma, CDMO, complex generics, consumer health, recovery, FY27 guidance, margins — [Source](https://www.moneycontrol.com/news/business/q1-growth-has-been-broad-based-across-businesses-says-piramal-pharma-chairperson-nandini-piramal-13989899.html)
- 2026-07-30 — The Hindu: **Piramal Pharma Limited Announces Results for Q1 FY27** — Piramal Pharma Limited Announces Results for Q1 FY27 — [Source](https://www.thehindu.com/brandhub/pr-release/piramal-pharma-limited-announces-results-for-q1-fy27/article71284206.ece)
- 2026-07-29 — CNBC-TV18: **Q1 Results LIVE Updates: Vedanta Power slips to loss, Eicher Motors beats estimates** — Q1 Results LIVE Updates: Four Nifty 50 stocks are reporting their earnings today namely Asian Paints, Adani Enterprises, Adani Ports and Eicher Motors. Dabur, Waaree Energies, ACME Solar, Bajaj Housing Finance, CarTrade Tech, Chalet Hotels, Colgate-Palmolive, J&K Bank, Hexaware Technologies, KPIT Tech, Garden Reach Shipbuilders, Force Motors, Dhanlaxmi Bank, Devyani International, MOIL, Piramal Pharma, Prestige Estates, Redington, Star Health Insurance, Syngene, Teamlease, Triveni Engineering, Zensar Tech are among the other earnings from the broader markets. L&T, Netweb Tech, among others will also be reacting to their results. Watch this space for all the LIVE Q1 results updates. — [Source](https://www.cnbctv18.com/market/q1-results-live-updates-asian-paints-adani-ports-ent-hul-eicher-bajaj-hsg-dabur-mtar-kpit-tech-cartrade-colgate-share-price-liveblog-19956225.htm)
- 2026-07-24 — CNBC-TV18: **Piramal Pharma temporarily suspends Ahmedabad plant operations due to heavy rainfall** — Shares of Piramal Pharma Ltd ended at ₹181.65, up by ₹0.80, or 0.44%, on the BSE. — [Source](https://www.cnbctv18.com/market/stocks/piramal-pharma-share-price-temporarily-suspends-ahmedabad-plant-operations-due-to-heavy-rainfall-19953734.htm)
- 2026-07-23 — Economic Times: **Pharma stocks slide as Trump's 100% generic drug tariff plan spooks investors** — Indian drug shares declined Wednesday following US President Trump's tariff announcement. These proposed tariffs will significantly impact companies with substantial US revenue exposure. Analysts suggest investors should now focus on domestically oriented Indian pharmaceutical firms. The Nifty Pharma index saw a notable decrease, while the benchmark Nifty 50 also fell. Negotiations are expected given India's vital role in supplying affordable medicines to the US. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/pharma-stocks-slide-as-trumps-100-generic-drug-tariff-plan-spooks-investors/articleshow/132570049.cms)
- 2026-07-22 — CNBC-TV18: **Sensex Today | Stock Market LIVE Updates: Nifty falls 200 points; Tata Comm down 5% after results** — Sensex Today | Stock Market LIVE Updates: We are in the second half of the day's trade and the markets remain under immense pressure, with the Nifty index falling over 150 points, slumping towards 24,000. The Nifty Bank is down over 500 points, slumping towards 57,300. IndiGo, Cipla and and SBI are the top laggards. — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-nifty-50-today-crude-bandhan-drl-adani-nestle-hpcl-eternal-bpcl-share-price-liveblog-19950949.htm)

## Business profile

**Strategic vision:** Global pharmaceutical company advancing healthcare through products and services.

### Business segments
- **Piramal Pharma Solutions:** Piramal Pharma Solutions operates as a Contract Development and Manufacturing Organization (CDMO) providing end-to-end development and manufacturing solutions across the drug lifecycle.
- **Piramal Critical Care:** Piramal Critical Care is a global provider of inhaled anesthetics and hospital generics, focusing on delivering critical care products to healthcare systems.
- **Piramal Consumer Healthcare:** Piramal Consumer Healthcare is a significant player in the Indian self-care market, offering a portfolio of branded consumer healthcare and wellness products.
- **AbbVie Therapeutics India Private Limited:** This joint venture is active in the ophthalmic category in India, providing medications and devices for various eye conditions.

### Competitive strengths
- Globally integrated network of facilities
- Science-led innovation
- Adherence to global quality and regulatory standards
- Diverse portfolio of products and services

## Related stocks

- [ABBOTINDIA (Healthcare)](https://faxioms.com/stocks/abbotindia) — +5.50%
- [ACUTAAS (Healthcare)](https://faxioms.com/stocks/acutaas) — +3.86%
- [AJANTPHARM (Healthcare)](https://faxioms.com/stocks/ajantpharm) — +1.61%
- [ALKEM (Healthcare)](https://faxioms.com/stocks/alkem) — +0.14%
- [ANTHEM (Healthcare)](https://faxioms.com/stocks/anthem) — -0.35%

## Freshness and sources

- Data as of: 2026-09-18
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/pplpharma
Markdown representation: https://faxioms.com/stocks/pplpharma?render=md